@article {HAN2821, author = {SE YOUNG HAN and BALKRISHNA N. JAHAGIRDAR and ARKADIUSZ Z. DUDEK}, title = {Two Malignancies With Differential Responses to Immune Checkpoint Inhibitors: A Case Report}, volume = {40}, number = {5}, pages = {2821--2826}, year = {2020}, doi = {10.21873/anticanres.14255}, publisher = {International Institute of Anticancer Research}, abstract = {Background: Immune checkpoint inhibitors (ICI) have changed the management of cancer dramatically. However, not all patients respond to ICI and their use places patients at a significant risk of immune-related adverse reactions. A few biomarkers including programmed death-1 receptor/programmed death-ligand 1 (PD-1/PD-L1), micro-satellite instability (MSI) status, and tumor mutational burden (TMB) have gained popularity as surrogates to predict responsiveness to ICI. Case Report: Herein, we report a 61-year-old male who was diagnosed with widespread metastatic adenocarcinoma and a discrete renal lesion. Most of the metastatic lesions, except the left kidney mass, responded to a combination immunotherapy. Subsequent left nephrectomy revealed a chromophobe renal cell carcinoma. With this multimodality approach, we were able to achieve a durable near complete remission in a patient with diffuse metastatic disease at diagnosis. Conclusion: In this report, we explored possible commercially available and experimental biomarkers in an attempt to explain his exceptional response.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/40/5/2821}, eprint = {https://ar.iiarjournals.org/content/40/5/2821.full.pdf}, journal = {Anticancer Research} }